Anca L Grosu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8260820/publications.pdf

Version: 2024-02-01

143	4,531	109137	128067
papers	citations	35 h-index	60 g-index

147	147	147	5792
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ESTRO-ACROP guideline â€œtarget delineation of glioblastomasâ€• Radiotherapy and Oncology, 2016, 118, 35-42.	0.3	286
2	An Interindividual Comparison of O-(2- [18F]Fluoroethyl)-L-Tyrosine (FET)â€“ and L-[Methyl-11C]Methionine (MET)â€“PET in Patients With Brain Gliomas and Metastases. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1049-1058.	0.4	222
3	How to use functional imaging information for radiotherapy planning. European Journal of Cancer, 2009, 45, 461-463.	1.3	160
4	PET imaging in patients with meningiomaâ€”report of the RANO/PET Group. Neuro-Oncology, 2017, 19, 1576-1587.	0.6	157
5	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2014, 113, 317-323.	0.3	141
6	Comparison of ⁶⁸Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics, 2017, 7, 228-237.	4.6	135
7	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2016, 121, 364-373.	0.3	130
8	Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men. Theranostics, 2014, 4, 412-419.	4.6	127
9	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(â^) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. Clinical Cancer Research, 2016, 22, 2639-2649.	3.2	127
10	Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer. JAMA Oncology, 2022, 8, e215445.	3.4	127
11	Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncology, The, 2020, 21, 581-592.	5.1	121
12	SBRT in pancreatic cancer: What is the therapeutic window?. Radiotherapy and Oncology, 2015, 114, 109-116.	0.3	85
13	[68Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard â€“ Implications for focal radiotherapy planning in primary prostate cancer. Radiotherapy and Oncology, 2019, 141, 214-219.	0.3	83
14	Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome. Radiotherapy and Oncology, 2015, 117, 113-117.	0.3	78
15	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. Neuro-Oncology, 2021, 23, 881-893.	0.6	75
16	Comparison of toxicity after IMRT and 3D-conformal radiotherapy for patients with pancreatic cancer â€“ A systematic review. Radiotherapy and Oncology, 2015, 114, 117-121.	0.3	73
17	Imaging and Selective Elimination of Glioblastoma Stem Cells with Theranostic Near-Infrared-Labeled CD133-Specific Antibodies. Theranostics, 2016, 6, 862-874.	4.6	71
18	MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 889-897.	3.3	68

#	Article	IF	Citations
19	Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) â€“ protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC Cancer, 2016, 16, 769.	1.1	62
20	Outcome After PSMA PET/CTâ€“Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis. Journal of Nuclear Medicine, 2019, 60, 227-233.	2.8	61
21	A deep conical agarose microwell array for adhesion independent three-dimensional cell culture and dynamic volume measurement. Lab on A Chip, 2018, 18, 179-189.	3.1	55
22	Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference. Radiation Oncology, 2018, 13, 81.	1.2	53
23	Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1463-1472.	3.3	51
24	Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms. Critical Reviews in Oncology/Hematology, 2018, 126, 13-18.	2.0	51
25	Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly?. Radiation Oncology, 2020, 15, 31.	1.2	51
26	Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68 Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference. Radiotherapy and Oncology, 2017, 123, 472-477.	0.3	50
27	Heat shock protein 70 and tumorâ€infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTKâ€ROG). International Journal of Cancer, 2018, 142, 1911-1925.	2.3	50
28	First statement on preparation for the COVID-19 pandemic in large German Speaking University-based radiation oncology departments. Radiation Oncology, 2020, 15, 74.	1.2	50
29	Re-irradiation for Recurrent Primary Brain Tumors. Anticancer Research, 2016, 36, 4985-4996.	0.5	47
30	Stereotactic fractionated radiotherapy for Klatskin tumours. Radiotherapy and Oncology, 2010, 95, 99-102.	0.3	44
31	Simultaneous integrated protection. Strahlentherapie Und Onkologie, 2016, 192, 886-894.	1.0	43
32	Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) â€“ a phase II prospective randomized multicenter trial (NOA-14, ARO 2015â€“3, DKTK-ROG). BMC Cancer, 2020, 20, 532.	1.1	43
33	Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. Radiotherapy and Oncology, 2019, 141, 208-213.	0.3	42
34	ESTRO ACROP guideline for target volume delineation of skull base tumors. Radiotherapy and Oncology, 2021, 156, 80-94.	0.3	41
35	Correlating Dose Variables with Local Tumor Control in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Modeling Study on 1500 Individual Treatments. International Journal of Radiation Oncology Biology Physics, 2020, 107, 579-586.	0.4	40
36	Impact of 4D-18FDG-PET/CT imaging on target volume delineation in SBRT patients with central versus peripheral lung tumors. Multi-reader comparative study. Radiotherapy and Oncology, 2015, 115, 335-341.	0.3	37

#	Article	IF	Citations
37	Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis. Radiotherapy and Oncology, 2018, 127, 121-127.	0.3	37
38	Uncovering the invisibleâ€"prevalence, characteristics, and radiomics featureâ€"based detection of visually undetectable intraprostatic tumor lesions in 68GaPSMA-11 PET images of patients with primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1987-1997.	3.3	37
39	Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA). Radiation Oncology, 2017, 12, 107.	1.2	35
40	Prostate-specific Membrane Antigen Positron Emission Tomographyâ€"detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. European Urology Focus, 2021, 7, 309-316.	1.6	34
41	Expert consensus on re-irradiation for recurrent glioma. Radiation Oncology, 2017, 12, 194.	1.2	32
42	Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapyâ€"results from a prospective trial. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1046-1055.	3.3	32
43	Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. Liver Cancer, 2019, 8, 281-294.	4.2	31
44	Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective. Radiographics, 2021, 41, 1387-1407.	1.4	30
45	11C-Choline PET/pathology image coregistration in primary localized prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2242-2248.	3.3	29
46	Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy. Acta OncolÃ³gica, 2016, 55, 1299-1304.	0.8	28
47	The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer. Radiotherapy and Oncology, 2020, 150, 128-135.	0.3	28
48	Multicenter analysis of stereotactic radiotherapy of the resection cavity in patients with brain metastases. Cancer Medicine, 2018, 7, 2319-2327.	1.3	27
49	Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis. BMC Cancer, 2018, 18, 807.	1.1	27
50	Intraindividual comparison between 68Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2796-2803.	3.3	27
51	A Novel MiRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy. PLoS ONE, 2015, 10, e0118745.	1.1	27
52	Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET. Radiation Oncology, 2018, 13, 159.	1.2	26
53	The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer. Radiation Oncology, 2018, 13, 65.	1.2	26
54	Improved inter-observer agreement of an expert review panel in an oncology treatment trial â€" Insights from a structured interventional process. European Journal of Cancer, 2015, 51, 2525-2533.	1.3	24

#	Article	IF	Citations
55	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. Radiotherapy and Oncology, 2018, 126, 125-131.	0.3	24
56	Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous. Radiation Oncology, 2019, 14, 33.	1.2	24
57	Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma. Radiotherapy and Oncology, 2019, 130, 121-131.	0.3	24
58	Comparison of Manual and Semi-Automatic [18F]PSMA-1007 PET Based Contouring Techniques for Intraprostatic Tumor Delineation in Patients With Primary Prostate Cancer and Validation With Histopathology as Standard of Reference. Frontiers in Oncology, 2020, 10, 600690.	1.3	23
59	Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer. EJNMMI Research, 2020, 10, 62.	1.1	23
60	Estimation of the Î±/Î² ratio of non-small cell lung cancer treated with stereotactic body radiotherapy. Radiotherapy and Oncology, 2020, 142, 210-216.	0.3	22
61	Stereotactic fractionated radiotherapy of the resection cavity in patients with one to three brain metastases. Clinical Neurology and Neurosurgery, 2016, 142, 81-86.	0.6	21
62	Digital Follow-Up and the Perspective of Patient-Centered Care in Oncology: Whatâ€™s the PROblem?. Oncology, 2020, 98, 379-385.	0.9	21
63	The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer. Radiation Oncology, 2020, 15, 81.	1.2	21
64	The role of albuminâ€“bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. Strahlentherapie Und Onkologie, 2018, 194, 403-413.	1.0	20
65	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. BMC Cancer, 2020, 20, 362.	1.1	20
66	Quality of life after pulmonary stereotactic fractionated radiotherapy (SBRT): Results of the phase II STRIPE trial. Radiotherapy and Oncology, 2020, 148, 82-88.	0.3	20
67	The impact of the co-registration technique and analysis methodology in comparison studies between advanced imaging modalities and whole-mount-histology reference in primary prostate cancer. Scientific Reports, 2021, 11, 5836.	1.6	20
68	Explainable AI for CNN-based prostate tumor segmentation in multi-parametric MRI correlated to whole mount histopathology. Radiation Oncology, 2022, 17, 65.	1.2	20
69	Local control and overall survival after frameless radiosurgery: A single center experience. Clinical and Translational Radiation Oncology, 2017, 7, 55-61.	0.9	19
70	Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature. Cancer Immunology, Immunotherapy, 2020, 69, 1823-1832.	2.0	19
71	Development and validation of a novel prognostic score for elderly head-and-neck cancer patients undergoing radiotherapy or chemoradiation. Radiotherapy and Oncology, 2021, 154, 276-282.	0.3	19
72	PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial. Cancers, 2021, 13, 5795.	1.7	19

#	Article	IF	Citations
73	Mesenchymal stem cells preserve their stem cell traits after exposure to antimetabolite chemotherapy. Stem Cell Research, 2019, 40, 101536.	0.3	18
74	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. Radiotherapy and Oncology, 2018, 127, 27-35.	0.3	17
75	Repeated SBRT for in- and out-of-field recurrences in the liver. Strahlentherapie Und Onkologie, 2019, 195, 246-253.	1.0	17
76	Prospective randomized clinical studies involving reirradiation. Strahlentherapie Und Onkologie, 2016, 192, 679-686.	1.0	16
77	Preserving the legacy of reirradiation: A narrative review of historical publications. Advances in Radiation Oncology, 2017, 2, 176-182.	0.6	16
78	Second re-irradiation: a narrative review of the available clinical data. Acta OncolÃ³gica, 2018, 57, 305-310.	0.8	16
79	Predicted survival in patients with brain metastases from colorectal cancer: Is a current nomogram helpful?. Clinical Neurology and Neurosurgery, 2016, 143, 107-110.	0.6	15
80	Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resection. Cancer Medicine, 2018, 7, 2350-2359.	1.3	15
81	Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life:Benefit for Patients With Low Initial Scores (STRIPE Trial). Journal of Thoracic Oncology, 2019, 14, 408-419.	0.5	15
82	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2328-2338.	3.3	13
83	Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference. Frontiers in Oncology, 2021, 11, 652678.	1.3	12
84	App-Controlled Treatment Monitoring and Support for Head and Neck Cancer Patients (APCOT): Protocol for a Prospective Randomized Controlled Trial. JMIR Research Protocols, 2020, 9, e21693.	0.5	12
85	Financial toxicity in cancer patients treated with radiotherapy in Germanyâ€”aÂcross-sectional study. Strahlentherapie Und Onkologie, 2022, 198, 1053-1061.	1.0	12
86	PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01). International Journal of Radiation Oncology Biology Physics, 2022, 113, 1025-1035.	0.4	12
87	The challenge of durable brain control in patients with brain-only metastases from breast cancer. SpringerPlus, 2015, 4, 585.	1.2	11
88	Short Survival Time after Palliative whole Brain Radiotherapy: Can We Predict Potential Overtreatment by Use of a Nomogram?. Journal of Cancer, 2017, 8, 1525-1529.	1.2	11
89	Unresectable hepatic PEComa: a rare malignancy treated with stereotactic body radiation therapy (SBRT) followed by complete resection. Radiation Oncology, 2018, 13, 28.	1.2	11
90	FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro. Strahlentherapie Und Onkologie, 2021, 197, 27-38.	1.0	11

#	Article	IF	Citations
91	Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. Frontiers in Oncology, 2021, 11, 640467.	1.3	11
92	Validation of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). Journal of Clinical Medicine Research, 2018, 10, 178-181.	0.6	11
93	Automatic Tumor Segmentation With a Convolutional Neural Network in Multiparametric MRI: Influence of Distortion Correction. Tomography, 2019, 5, 292-299.	0.8	11
94	Comparison of GeneChip, nCounter, and Real-Time PCRâ€“Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. Journal of Molecular Diagnostics, 2020, 22, 801-810.	1.2	10
95	Surviving Elderly Patients with Head-and-Neck Squamous Cell Carcinomaâ€”What Is the Long-Term Quality of Life after Curative Radiotherapy?. Cancers, 2021, 13, 1275.	1.7	10
96	Gastrin-Releasing Peptide Receptor Antagonist [68Ga]RM2 PET/CT for Staging of Pre-Treated, Metastasized Breast Cancer. Cancers, 2021, 13, 6106.	1.7	10
97	Long-term survival results after treatment for oligometastatic brain disease. Reports of Practical Oncology and Radiotherapy, 2020, 25, 307-311.	0.3	9
98	Multimodal imaging for radiation therapy planning in patients with primary prostate cancer. Physics and Imaging in Radiation Oncology, 2018, 8, 8-16.	1.2	8
99	Biological imaging for individualized therapy in radiation oncology: part II medical and clinical aspects. Future Oncology, 2018, 14, 751-769.	1.1	7
100	Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis. Cancers, 2020, 12, 3395.	1.7	7
101	Prostate cancer tumour control probability modelling for external beam radiotherapy based on multi-parametric MRI-GTV definition. Radiation Oncology, 2020, 15, 242.	1.2	7
102	Impact of a low FODMAP diet on the amount of rectal gas and rectal volume during radiotherapy in patients with prostate cancer â€“ a prospective pilot study. Radiation Oncology, 2020, 15, 27.	1.2	7
103	Radiotherapeutic management of cervical lymph node metastases from an unknown primary site â€“ experiences from a large cohort treated with modern radiation techniques. Radiation Oncology, 2020, 15, 80.	1.2	7
104	Treatment outcomes of elderly salivary gland cancer patients undergoing radiotherapy â€“ Results from a large multicenter analysis. Radiotherapy and Oncology, 2021, 156, 266-274.	0.3	7
105	Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models?. Radiotherapy and Oncology, 2021, 159, 17-20.	0.3	7
106	Development of a Score Predicting Survival after Palliative Reirradiation. Journal of Oncology, 2014, 2014, 1-7.	0.6	6
107	Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA). Radiation Oncology, 2020, 15, 35.	1.2	6
108	ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. Pharmacogenomics Journal, 2021, 21, 37-46.	0.9	6

#	Article	IF	Citations
109	Evolution of the hypoxic compartment on sequential oxygen partial pressure maps during radiochemotherapy in advanced head and neck cancer. Physics and Imaging in Radiation Oncology, 2021, 17, 100-105.	1.2	6
110	Impact of radiotherapy protocol adherence in NSCLC patients treated with concurrent chemoradiation: RTQA results of the PET-Plan trial. Radiotherapy and Oncology, 2021, 163, 32-38.	0.3	6
111	Isotropic Expansion of the Intraprostatic Gross Tumor Volume of Primary Prostate Cancer Patients Defined in MRIâ€"A Correlation Study With Whole Mount Histopathological Information as Reference. Frontiers in Oncology, 2020, 10, 596756.	1.3	5
112	Hyperthermia Plus Re-Irradiation in the Management of Unresectable Locoregional Recurrence of Breast Cancer in Previously Irradiated Sites. Journal of Clinical Oncology, 2020, 38, 3576-3577.	0.8	5
113	A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa. Frontiers in Oncology, 2021, 11, 723536.	1.3	5
114	Changes in Blood Biomarkers of Angiogenesis and Immune Modulation after Radiation Therapy and Their Association with Outcomes in Thoracic Malignancies. Cancers, 2021, 13, 5725.	1.7	5
115	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. Radiotherapy and Oncology, 2022, 167, 300-307.	0.3	5
116	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC â€“ Hypothesis generation on a multicentre cohort of the DKTK-ROG. Radiotherapy and Oncology, 2022, 169, 8-14.	0.3	5
117	Influence of inhomogeneous radiosensitivity distributions and intrafractional organ movement on the tumour control probability of focused IMRT in prostate cancer. Radiotherapy and Oncology, 2018, 127, 62-67.	0.3	4
118	Retroperitoneal soft tissue sarcoma: low-dose neoadjuvant radiation therapy followed by surgery with or without intraoperative radiotherapy and adjuvant radiation therapy. Strahlentherapie Und Onkologie, 2019, 195, 558-565.	1.0	4
119	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. Radiotherapy and Oncology, 2022, 171, 91-100.	0.3	4
120	Normal tissue studies in radiation oncology: A systematic review of highly cited articles and citation patterns. Oncology Letters, 2014, 8, 972-976.	0.8	3
121	Imaging for radiation treatment planning and monitoring in prostate Cancer: Precision, personalization, individualization of therapy. Physics and Imaging in Radiation Oncology, 2019, 11, 61-62.	1.2	3
122	Does overall treatment time impact on survival after whole-brain radiotherapy for brain metastases?. Clinical and Translational Oncology, 2011, 13, 885-888.	1.2	2
123	Biological imaging for individualized therapy in radiation oncology: part I physical and technical aspects. Future Oncology, 2018, 14, 737-749.	1.1	2
124	ACTR-49. PriCoTTF: A PHASE I/II TRIAL OF TUMOR TREATING FIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi22-vi23.	0.6	2
125	Value of PET imaging for radiation therapy. Nuklearmedizin - NuclearMedicine, 2021, 60, 326-343.	0.3	2
126	Human mesenchymal stromal cells maintain their stem cell traits after high-LET particle irradiation â€“ Potential implications for particle radiotherapy and manned space missions. Cancer Letters, 2022, 524, 172-181.	3.2	2

#	Article	IF	Citations
127	Human Mesenchymal Stromal Cells Do Not Cause Radioprotection of Head-and-Neck Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2022, 23, 7689.	1.8	2
128	Hypoxia and positron emission tomography in patients with gliomas. Clinical and Translational Imaging, 2017, 5, 447-453.	1.1	1
129	The Role of Particle Therapy for the Treatment of Skull Base Tumors and Tumors of the Central Nervous System (CNS). Topics in Magnetic Resonance Imaging, 2019, 28, 49-61.	0.7	1
130	A 6-gene signature for outcome prediction of grade II/III glioma.. Journal of Clinical Oncology, 2014, 32, 2002-2002.	0.8	1
131	Molecular Imaging in Photon Radiotherapy. Recent Results in Cancer Research, 2020, 216, 845-863.	1.8	1
132	Improvement of diffusion weighted MRI by practical B0 homogenization for head & neck cancer patients undergoing radiation therapy. Physica Medica, 2022, 97, 59-65.	0.4	1
133	Abstract 3156: Tumor Treating Fields reduce cellular survival of human mesenchymal stromal cells via apoptosis and senescence induction. Cancer Research, 2022, 82, 3156-3156.	0.4	1
134	Scientific impact of studies published in temporarily available radiation oncology journals: a citation analysis. SpringerPlus, 2015, 4, 93.	1.2	0
135	GENE-27. GENOME-WIDE DNA METHYLATION PROFILING IN GRADE II AND III GLIOMAS REVEALS A SUBSET OF GENES WITH PROGNOSTIC SIGNIFICANCE CONTROLLED BY PROMOTER METHYLATION. Neuro-Oncology, 2018, 20, vi109-vi109.	0.6	0
136	CSIG-21. THE ROLE OF miR-219a-2-3p AS A TUMOR SUPPRESSOR IN IDH1/2-WILD-TYPE GRADE II/III GLIOMAS. Neuro-Oncology, 2018, 20, vi47-vi47.	0.6	0
137	Radiate Once More. International Journal of Radiation Oncology Biology Physics, 2021, 109, 314-315.	0.4	0
138	Measuring breathing induced oesophageal motion and its dosimetric impact. Physica Medica, 2021, 88, 9-19.	0.4	0
139	Randomized Controlled Clinical Trials in Radiation Therapy: Patterns of Publication in the Most Frequently Cited Studies. Medical Science Review, 0, 2, 104-110.	0.0	0
140	Mathematical Description of Changes in Tumour Oxygenation from Repeated Functional Imaging. Advances in Experimental Medicine and Biology, 2018, 1072, 195-200.	0.8	0
141	CTNI-79. PRICOTTF TRIAL: A PHASE I/II TRIAL OF TTFIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii61-ii61.	0.6	0
142	Implementation of PSMA-PET in focal dose-escalated radiotherapy of primary prostate cancer patients: Results of a planned safety analysis of a phase II trial.. Journal of Clinical Oncology, 2022, 40, 260-260.	0.8	0
143	Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. European Urology, 2022, , .	0.9	0